Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study

• Published in: BMC cancer Vol. 20; no. 1; p. 24
• Main Authors: Ge, Jing-Jing, Li, Cheng, Qi, Shao-Pei, Xue, Feng-Jun, Gao, Zhi-Meng, Yu, Chun-Jiang, Zhang, Jun-Ping
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.01.2020; BioMed Central; BMC
• Subjects: Analysis; Angiogenesis; Antiepileptic agents; Antineoplastic agents; Bevacizumab; Brain cancer; Brain tumors; Cancer; Cancer treatment; Carboplatin; Care and treatment; Chemotherapy; Combination drug therapy; Cytotoxic agents; Cytotoxicity; Development and progression; Endostatin; Enrollments; Glioblastoma; Glioblastomas; Gliomas; Irinotecan; Medical prognosis; Oncology; Patients; Radiation therapy; Recombinant human endostatin; Recurrence (Disease); Recurrent disseminated glioblastoma; Surgery; Survival; Temozolomide; Time; Toxicity; Tumors; Vincristine; Irinotecan; Recurrent disseminated glioblastoma; Chemotherapy; Temozolomide; Recombinant human endostatin
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-019-6467-6

The optimal chemotherapeutics of recurrent disseminated glioblastoma has yet to be determined. We analyzed the efficacy and safety of recombinant human endostatin (rh-ES) combined with temozolomide and irinotecan in patients with recurrent disseminated glioblastoma. We retrospectively reviewed 30 adult patients with recurrent disseminated glioblastoma treated with this combination chemotherapy at Department of Neuro-Oncology, Sanbo Brain Hospital, Capital Medical University of China from November 2009 to August 2018. Temozolomide was given orally at 200 mg/m daily for 5 days and rh-ES was administrated 15 mg/d daily for 14 days of each 28-day treatment cycle. Irinotecan was given intravenously every 2 weeks on a 28-day cycle at 340 mg/m or 125 mg/m depending on antiepileptic drugs. Primary endpoint was progression-free survival (PFS) at 6 months (6 m-PFS). The 6 m-PFS was 23.3%. The median PFS was 3.2 months. The overall survival rate (OS) at 12 months was 28.6%. The median OS was 6.9 months. Six out of 30 (20%) patients demonstrated partial radiographic response and 11 (36.7%) remained stable. The PFS of the 6 patients who got partial response was 5.8, 6.3, 6.9, 13.6, 15.8 and 16.6 months, respectively, and the median time interval of first response was 4 (range, 2.0-6.6) months. The most common adverse events were hematologic toxicities and gastrointestinal effects. The Grade ≥ 3 adverse event was hematologic toxicities. The adverse events were manageable. Rh-ES, in combination with cytotoxic drugs, was an alternative effective regimen with manageable toxicities in treatment of recurrent disseminated glioblastoma.